The Bright Side of Biologic Stability: A Thermofluor Screen for Rational Buffer Optimisation
Learn about the challenges of stabilising injectable biologics.
A Thermofluor Screen for the Rational Formulation of Injectable Therapeutic Protein Solutions
Project Management Spotlight with Sophie Skinner
Discover more about our team. In this Spotlight, meet our Project Coordinator, Sophie Skinner, on her journey with Upperton.
CMC Considerations for Early-Stage Drug Development
Addressing CMC considerations early in the drug development process is vital in the successful creation of a pharmaceutical product.
What is CMC in Pharmaceutical Development?
CMC refers to the set of activities that ensure a drug product is consistently produced, controlled, and meets the required quality standards.
CMC in the Drug Development Process
Without a strong CMC strategy, even a promising drug candidate can fail to reach the market. Discover the foundation for product development.
Management Spotlight with Danielle Young
Discover more about our team. In this Spotlight, meet our QC Manager, Danielle Young, on her journey with Upperton.
What It Means for Upperton to Be a Living Wage Employer
We’re delighted to share that Upperton has officially been accredited as a Living Wage Employer, joining over 15,000 UK employers.
Dry Powder Formulation: The Next Generation
Outlining the Trends and Challenges in the Inhaled Drug Delivery Market, with a Special Focus on Dry Powder Formulation.
Upperton completes build of new £15m development and GMP manufacturing facility
Leading UK contract development and manufacturing organisation (CDMO), Upperton Pharma Solutions has completed the build of its new development and GMP manufacturing headquarters in Nottingham, UK. Situated less than two miles from Upperton’s current HQ, the facility ‘Trent Gateway’ houses ten new GMP manufacturing suites, quality control laboratories and formulation development with pilot plant capabilities. […]